Document Detail

Prognostic value of melanoma-associated antigen A9 in renal cell carcinoma.
MedLine Citation:
PMID:  23140095     Owner:  NLM     Status:  Publisher    
Abstract Objective. The aim of this study was to evaluate the prognostic relevance of melanoma-associated antigen (MAGE) A9 in renal cell carcinoma (RCC). Material and methods. Immunohistochemical staining for MAGE A9 was evaluated in a tissue microarray containing 587 RCC tumour tissue samples. Nuclear MAGE A9 expression was reviewed using a semiquantitative score. Follow-up has been surveyed since 1990 in a prospectively conducted tumour database. The effect of MAGE A9 expression on cancer-specific survival (CSS) was assessed by univariate and multivariate Cox regression analyses. Subgroup analyses were performed for non-metastatic and metastatic disease. Results.Median age in all patients was 63.2 years, 354 patients were male and 233 female, and 108 patients had metastatic disease. Median follow-up was 5.6 years for all patients and 9.0 years for patients still alive (range 0-19.9 years). High nuclear MAGE A9 expression was present in 326 tumour specimens (55.5%). In multivariate analyses high nuclear MAGE A9 expression was associated with poor CSS (p = 0.0027). Furthermore, tumour stage, lymph-node and distant metastasis, Fuhrman grade G3/4, Karnofsky index < 80% and male gender were associated with poor CSS. In subgroup analyses, results were concordant for patients with non-metastatic disease. In patients with metastatic disease, only Karnofsky index > 80% was a significant predictor for CSS; MAGE A9 expression could not be shown to be associated with CSS (p = 0.161). Conclusions.High nuclear MAGE A9 expression is independently associated with poor CSS in patients with non-metastatic RCC. The assessment of MAGE A9 expression can provide additional prognostic information and should be used in decision-making regarding adjuvant therapy in patients with non-metastatic disease.
Gencay Hatiboglu; Maria Pritsch; Stephan Macher-Goeppinger; Margot Zöller; Johannes Huber; Axel Haferkamp; Sascha Pahernik; Nina Wagener; Markus Hohenfellner
Related Documents :
717395 - Prognostic value of nucleoli and cell size in chronic lymphocytic leukemia.
19157325 - Response of imitanib meysylate in patients with gastrointestinal stromal cell tumour.
10190945 - Fludarabine treatment in b-cell chronic lymphocytic leukemia: response, toxicity and su...
24227985 - Efficacy of vincristine and carboplatin as chemo-reduction for advanced bilateral retin...
24586605 - Braf-v600 mutations have no prognostic impact in stage iv melanoma patients treated wit...
11016705 - Low-dose induction radiotherapy for stomach conservation in patients with massive gastr...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-12
Journal Detail:
Title:  Scandinavian journal of urology and nephrology     Volume:  -     ISSN:  1651-2065     ISO Abbreviation:  Scand. J. Urol. Nephrol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0114501     Medline TA:  Scand J Urol Nephrol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Urology.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Breast self-examination and breast cancer awareness in women in developing countries: a survey of wo...
Next Document:  Leaf endophyte load influences fungal garden development in leaf-cutting ants.